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supporting the family to ensure the best possible out-
comes in the face of certain death. Unfortunately, there is
a lack of research evidence on which to base such care
[3-7]. The terminal outcome of the disease may be
known, but the onset, timing, patterns, and severity of
symptoms are not; consequently, best practices and stra-
tegies for symptom relief are also unknown. Furthermore,
little is understood about the bio-psychosocial-spiritual
impact on these families and how to support them.
There is a critical need to develop a solid understand-
ing of disease progression and the experiences of these
children and their families over time. We are currently
conducting an innovative 5-year longitudinal study to
identify and track children diagnosed with progressive
metabolic, neurological, or chromosomal conditions and
their families to determine and document the clinical
progression of the condition and the associated bio-psy-
chosocial-spiritual experiences of the family. Our goal is
to close the key knowledge gaps and provide new infor-
mation about the best care for these vulnerable children
and their families. Our purpose in this paper is to
describe the rationale, development, design, and imple-
mentation of this study to assist other researchers who
may be interested in conducting longitudinal research.
Background
Our research team, Transitions in Pediatric Palliative
Care and End of Life, was funded by the Canadian Insti-
tutes of Health Research (CIHR) under the New Emer-
ging Team Program (NET) (PET-697#). Led by Dr. Hal
Siden and known as PedPalNet, this team was conceived
to develop a sustainable research program focused on
creating knowledge to optimize provision of care for
children with life-threatening conditions. As far as we
are aware, this is the first interprofessional, multi-centre
team of researchers in pediatric palliative care in the
world. We work together to develop specific research
projects, obtain project operating funds, attract new
research collaborators, and increase research capacity
through trainee support and mentoring.
In an early PedPalNet project, we conducted a Delphi
process to identify high-value areas for Canadian
pediatric palliative care clinicians and researchers.
Through that project, we identified four thematic areas,
three of which have particular relevance to this current
study: (1) identifying what matters most to families; (2)
providing relief of symptoms; and (3) developing evi-
dence to support best practice [8]. A foundational
cohort study to identify family experiences and symp-
tom courses is a logical sequela to the Delphi project.
Dr. Rose Steele, one of the co-principal investigators
for the current study, previously conducted research
with families living with a child who has a neuro-degen-
erative illness. The resulting grounded theory identified
the basic social process of ‘navigating uncharted terri-
tory’ and outlined the trajectory, impact on the family,
factors that modified the experience, and strategies used
by families to manage the experience [9-13]. Lack of
information about what could be expected in the illness
trajectory was identified as seriously hampering a
family’s ability to manage the experience. The current
study, Charting the Territory, builds on the grounded
theory study by focusing on children with a wider range
of progressive metabolic, neurological, or chromosomal
conditions and by using a longitudinal design to
describe the symptom trajectory and further understand
the whole experience for the child, siblings, and parents
from a quantitative perspective.
Life-Threatening Conditions in Children
Two seminal reports from the United Kingdom [14] and
the United States [7] described the broad spectrum of
diagnoses of life-threatening conditions encountered in
children. These conditions are physiologically diverse,
vary in life expectancy and treatments, and more or less
fall into four Quadrants [14] (see Table 1).
Our study focuses on children with Quadrant 3-type
conditions. Quadrant 3-type conditions are those with-
out cure or life-prolonging treatment; good symptom
management and treatment of comorbid illnesses are
emphasized (e.g., aspiration pneumonia) but do not alter
the underlying pathophysiological process. The process
remains inherent in the disease condition. Examples of
diseases that are commonly thought of as fitting into
Table 1 Quadrants of Life-Threatening Conditions in Children[14]
Quadrant 1 Quadrant 2
Life threatening conditions for which curative treatment may be
feasible but can fail.
Conditions where premature death is inevitable, but long periods of
intensive treatment aimed at prolonging life and allowing participation in
normal activities
(e.g., cancer, irreversible organ failures) (e.g., cystic fibrosis)
Quadrant 3 Quadrant 4
Progressive conditions without curative treatment options, where
treatment is exclusively palliative and may extend over many years.
Irreversible but non progressive conditions with severe disability susceptible
to health complications and premature death.
(e.g., neurodegenerative, metabolic disease) (e.g., anoxic brain injury, severe cerebral palsy)
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this category include: leukodystrophies, spinocerebellar
degenerative diseases, and some chromosomal anoma-
lies, including aneuploid states. Even though the specific
diagnoses that tend to fall into Quadrant 3 are varied
and numerous, clinically they are similar in functional
impairments and diversity of symptoms that limit qual-
ity and duration of life.
The number of children with rare, progressive diseases
that fall into Quadrant 3 is large relative to the other
Quadrants and these children require significant health
care attention, yet surprisingly little has been compre-
hensively explored and documented about the illness
trajectory of these conditions. The onset of the disease
and symptoms and the length of survival time for these
children are virtually unexplored. We chose to conduct
research with this group for several reasons:
• These children and their families are major users
of health care services for acute, chronic, and end-
of-life care [2].
• There is a major impact on families caring for
these children [15].
• These children account for about 50% of children
receiving palliative care [16-22].
• As a group, Quadrant 3-type conditions are a sig-
nificant cause of death in childhood [1,19,23,24].
• There is a lack of research in this group compared
with other areas, such as cancer [25].
Knowledge Gaps
Both positive and negative outcomes of the experience
have been documented for parents and siblings of these
children [9-11,13,26-32] but there is a paucity of
research addressing the overall experience of the child
and family. It is unclear if outcomes are isolated to spe-
cific times, if they are present throughout the experi-
ence, or if/how they may change over time. A holistic
approach that concurrently examines bio-psychosocial-
spiritual dimensions for family members would allow for
a more complete picture of the experience.
Given the prevalence of Quadrant 3-type conditions
and the associated physical, psychological, and financial
costs, it became clear that a longitudinal, prospective
study that follows the child and family for as long as
possible as they move from diagnosis through death and
into bereavement was imperative to document the nat-
ural course of the child’s condition and the experience
of the family. This study was conceived as a way to
address this important research area. Results of this
study will inform families and clinicians about what they
might anticipate during the child’s trajectory towards
death.
Methods/Design
Study Objectives
Our study is a prospective longitudinal study with three
objectives:
a) Establish a cohort of children with non-curable,
life-threatening conditions.
b) Determine and document the natural history of
the symptom progression of these conditions.
c) Determine and document the bio-psychosocial-
spiritual trajectory of parents and siblings.
Specific research questions include:
1. What is the clinical illness trajectory, and its
impact, for children with non-curable, life-threaten-
ing conditions, specifically: pain, breathing or
respiratory problems, feeding difficulties, alertness
and interaction changes, sleep problems, seizures,
constipation, and functional abilities?
2. What is the bio-psychosocial-spiritual trajectory,
and its impact, for families when a child has a non-
curable, life-threatening condition, specifically out-
come variables of: family functioning; marital satis-
faction; parent health, anxiety, depression, stress,
burden, spirituality, grief, and growth; and sibling
health and coping?
3. Do these child and family outcome variables
change over time?
4. What relationships exist among the child and
family outcome variables and do these relationships
change over time?
Study Design
In this longitudinal research study, we are using quanti-
tative methods with established instruments and chart
reviews. Data collection is taking place along two paral-
lel streams: one examining the child’s clinical symptoms,
and the other examining bio-psychosocial-spiritual
aspects of the experience for family members. Under the
current funding, children and their families will be fol-
lowed for a minimum of 18 months, based on when
they enter the study. However, we hope to obtain
further funding beyond this initial 5-year study and
extend this cohort for a longer duration. We also hope
to expand data collection in the future to include quali-
tative interviews that capture other aspects of the
experience. We are recruiting children and families with
new diagnoses in order to maximize understanding of
the condition trajectory, but we also are including those
with established diagnoses as some symptoms may only
arise later in the condition course. This approach should
Siden et al. BMC Pediatrics 2010, 10:67
http://www.biomedcentral.com/1471 2431/10/67
Page 3 of 12
provide an opportunity to better understand symptoms
and parent/sibling experiences at different times along
the trajectory. Some children may die during the study
period, but the intent is to follow those families through
the course of the illness and into bereavement. This
descriptive, correlational design will allow for efficient
and effective collection of large amounts of data within
a naturalistic setting and for investigation of complex
relationships that may exist among the clinical and bio-
psycho-social variables.
Eligibility Criteria
Only children with Quadrant 3-type conditions that fall
into the group of progressive metabolic, neurological, or
chromosomal conditions are eligible for the study. Chil-
dren who have been provided with potentially curative
therapies, such as stem cell transplantation for metabolic
conditions, are excluded. The inclusion list was devel-
oped from a literature review, palliative care program
data (Canuck Place Children’s Hospice, Vancouver), and
an iterative review process involving pediatric palliative
care physicians and specialists in the fields of Neurology,
Genetics, and Metabolic Diseases. The resultant list is in
accordance with current approaches to pediatric pallia-
tive care [14] and work on mortality in childhood Com-
plex Chronic Conditions [23,33].
Determining who is eligible for recruitment from a
theoretical “Quadrant” of conditions initially proved
challenging. The Quadrant model, first described as
“Categories” by the British charity ACT, is primarily
useful as a conceptual framework for understanding the
broad variety of children and families receiving pediatric
palliative care. Clinically, the model maps broadly onto
an identifiable population of eligible children. Before
recruitment started, the clinicians began to generate a
list of sample eligible diseases in order to establish who
would be specifically eligible. From the original list, a
system of categories was further developed by geneti-
cists, neurologists, and biochemical disease specialists in
our study sites. This list included a category for those
conditions that could be treated with curative therapies,
but where the child would be eligible if the treatment
was failing, and those conditions where the trajectory
may not always display the progressive component that
is classic for Quadrant 3. The list quickly became itera-
tive in that the clinicians and researchers continue to
make notes and compare their new diagnoses to the ori-
ginal list, adding and noting where there is disagree-
ment. This purposive sampling of diagnoses allows the
inclusion of children whose disease is progressive, and
the constant iterations permit a theoretical model
to translate into a practical, useful clinical document to
determine eligibility. Potential participants are compared
to the list and to an Eligibility Criteria Checklist to
determine whether or not to approach the family (see
Figure 1).
Families may have various ways of determining who is
a member of their family, but for the purposes of this
study, “family” includes only the biological, adoptive,
step-parents, or legal guardian and biological, adoptive,
or step-siblings with whom the affected child lives most
of the time. Children in foster care are not eligible
because some foster parents only provide short-term
care, the foster setting may change during the course of
the study, or there may be legal issues with obtaining
consent. Families who have multiple children affected
with these conditions are eligible, but only those affected
children 0-19 years of age are included in the study. A
parent may provide data about more than one eligible,
affected child. A minimum of one parent must agree to
participate on his/her own behalf, plus provide the
required information on the ill child throughout the
study. In addition, all siblings age 7-18 years are invited
to participate. The age ranges were chosen because the
instruments we are using have been validated for chil-
dren of those ages. Participants must speak and write
English or French as data collection is only available in
the two official Canadian languages.
Study Recruitment
Three hundred children and their families are being
recruited in six cities across Canada (Vancouver, Cal-
gary, Edmonton, Toronto, Ottawa, and Montreal). Sites
were chosen to maximize access to the population based
on (a) the numbers of children diagnosed annually, (b)
the presence of a palliative care team member as an
onsite collaborator for recruitment and ethics, and (c)
the availability of a specialist clinician/team in Metabolic
Diseases, and/or Genetics, and/or Neurology clinics who
follow these children and can support access to subjects
and clinic records. Prior to commencing recruitment at
a participating site, institutional ethics approval was
obtained from the Research Ethics Board (REB) of the
hospital, as well as from each of the universities where
the participating co-investigators held their primary aca-
demic positions.
The protocol and all study materials underwent minor
modifications to accommodate different requirements at
each site. These differences primarily reflect the varying
approaches of Research Ethics Boards regarding recruit-
ment. Each REB approved a different method of initial
contact between the researchers and the study partici-
pants. In provinces where Health Information Protection
legislation is strictest, the Research Assistant (RA) is
prohibited from contacting families without written
approval from at least one of the parents. At other sites,
contact information is accessible to the RA who may
call or visit with a family in clinic after an introduction
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Figure 1 Eligibility Criteria Checklist
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from the clinician or clinic nurse. All sites approved the
more passive “call back” method, where clinicians mail
out invitations from the clinic to the family. Families
who are interested call a toll-free 1-800 number for
more information. The site RA provides any follow-up
information for interested families. None of the sites
allow the researchers to recruit the families directly,
especially in situations where the Site Investigator also
tends to be the child’s clinician. This non-coercive pro-
cedure is intended to prevent undue pressure on the
family to participate.
When the initial recruitment met with challenges,
especially where the RA requires a lengthy introduction
process or is unable to identify eligible children due to
privacy protection laws, two alternate recruitment meth-
ods were added to the protocol. In order to maximize
the scope of our enrollment, an online recruitment
method was proposed. The REB approved clinicians
giving out information about our study website. Sec-
ondly, disease-specific organizations such as the MPS
Society, and other organizations such as the Rare Dis-
eases Foundation and the Canadian Organization for
Rare Disorders (CORD), are able to aid in recruitment
of eligible families by distributing information about the
study on their website and in organizational newsletters.
Each organization also has a list of parent support net-
works to which appeals can be made for assistance with
study recruitment.
Accrual and Attrition
The sample size of 300 is pragmatically motivated as we
anticipate that 50 participant families can be recruited
in each of the 6 sites. We are confident this sample size
is ample for descriptive purposes, e.g., it will enable us
to estimate simple proportions with a standard error not
exceeding.03. Across the collaborating sites, approxi-
mately 300 children are diagnosed annually with the
eligible rare, progressive conditions and another 750 chil-
dren are followed in the clinics. Therefore, about 1650
families would be eligible or become eligible over the 36
month accrual period. Based on previous work investi-
gating recruitment and retention in a longitudinal pallia-
tive care study, typically 80-90% of individuals are
expected to be receptive to research [34], so a sample
size of 300 is feasible. As with any longitudinal study,
attrition will likely occur over time, but parents in
pediatric palliative care often participate in research as a
way of helping others, even when they find it challen-
ging practically (e.g., time) or emotionally (e.g., reliving
memories) [11].
We anticipate minimizing attrition through employing
a number of strategies highlighted in the literature
[35-38]. RAs develop a solid relationship with families
through an initial face-to-face visit, telephone contact at
prescribed intervals, and letters to thank families for
their participation. Continuity of RAs is expected to
contribute to the trusting relationship that is needed to
help participants feel more connected to and interested
in the study over time. Efforts are made to respect
families’ time and recognize the value of their contribu-
tion. RAs schedule data collection at the family’s conve-
nience and regularly express verbal and written
appreciation for their participation in the study. In addi-
tion, along with the blank questionnaire package at each
6-month data collection point, including at baseline, and
regardless of how many family members participate,
families are given a cheque for $40 as a token of appre-
ciation. We expect that some parents may use the
money to help pay for respite while they complete the
questionnaires, but there are no restrictions on how par-
ents can spend the token of appreciation.
Data Collection
Data collection is taking place along two parallel time-
lines: one recording the child’s clinical symptoms
monthly and the other examining bio-psychosocial-spiri-
tual aspects of the experience for family members every
6 months. Instruments being used in the study are
detailed in Table 2 with information about who com-
pletes each instrument and how frequently it is com-
pleted. Data are also collected through chart reviews on
entry into the study and at the end of the study or at
the time of the child’s death. Data collection will con-
tinue for a minimum of 18 months, depending on how
early a family enrols in the study, providing a minimum
of 4 data collection points. The method and frequency
of data collection were chosen based on longitudinal
studies with seriously ill adults that indicate trends/
changes should be detectable with this timeline, while
minimizing burden as much as possible on individuals
who already have significant burdens placed upon them
due to the nature of their caregiving experience [37,39].
The questionnaire package and the timing of data col-
lection were previously reviewed and discussed with par-
ents of children with a life-threatening condition who
had at least one child enrolled on a hospice program.
These parents agreed the study was feasible and the
burden on families would not be too great.
We prefer that baseline data, including written
informed consent in accordance with institutional ethics
guidelines, are collected in person in order to establish a
relationship between the RA and the family from the
beginning of the study. However, occasionally a family
may be unable to participate in a face-to-face meeting
and so we have developed a telephone process for
explaining the study and arranging for families to sub-
mit written consent and completed questionnaires with-
out actually meeting with the RA. Questionnaire
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packages are mailed to these families for initial and sub-
sequent data collection. For the newly diagnosed family,
baseline data ideally is obtained before changes occur,
so within 4-6 weeks of diagnosis, but families where the
child has an established diagnosis may be recruited at
any stage in the disease process. Assent/consent (the
distinction being based on age) is obtained from all
child participants who are cognitively able to assent/
consent for themselves.
No further consent forms will be signed during the
study. Completed questionnaires signify ongoing con-
sent. At each data collection point, families are
reminded in the preamble to the questionnaire of their
right to refuse participation at any time or to not answer
certain questions. To ensure privacy and confidentiality
for returns from multiple members of a family, separate
envelopes are included for each participating subject to
seal their questionnaires before placing them in the
larger pre-paid, self-addressed return envelope.
Clinical symptoms stream
Data about the ill child’s clinical symptoms are collected
monthly using an online instrument designed by the
research team in consultation with other experienced
Canadian clinicians, families, and a psychometrician.
The instrument is a modification of the PediQUEST
symptom recording tool and the revised Memorial
Symptom Assessment Scale (7-12), developed for symp-
toms in children with cancer [40-43]. Symptoms are
being tracked for timing of onset (symptom latency)
[44], frequency, and distress. Assessed symptoms include
difficulties with breathing or respiration, feeding issues,
pain, alertness and interaction, sleep issues, seizures,
and constipation. Parents of children who received
palliative care services from the Canuck Place Children’s
Hospice reviewed the instrument and affirmed that it
includes the most common and/or troublesome symp-
toms. The instrument takes 6 to 10 minutes to complete
and parents may choose either an online or telephone
method of completion. If the parent chooses the online
method, s/he receives an email every month with a
reminder to visit the secure website and complete a web
survey. If the parent chooses the telephone method, the
RA calls at monthly intervals to administer the instru-
ment and enter the scores manually into the online
Table 2 Instruments, Participant Who Completes, and Timing of Data Collection
Instrument Who Completes Timing
Demographic
Information
Demographic Sheet Completed by parent Baseline and updated every 6 months
Family Level
Data
Family Adaptability and
Cohesion Evaluation Scale
(FACES III)[61]
Completed separately by each parent who agrees to
participate in study
Baseline and every 6 months
Couple Level
Data
Norton Quality of Marriage
Index[62]
Completed separately by each parent who agrees to
participate in study, when currently in spousal/
common law relationship
Baseline and every 6 months
Individual Level
Data: Parent
• SF 12[63]
• State Trait Anxiety
Inventory[64]
• Center for Epidemiologic
Studies Depression Scale
(CES D)[65]
• Perceived Stress Scale[66]
• Burden Scale[67]
• Post Traumatic Growth
Inventory (PTGI)[68]
• Spiritual Involvement and
Beliefs Scales (SIBS)[69]
• Grief Scale
• Impact of Participation
Completed separately by each parent who agrees to
participate in study
All at baseline and every 6 months,
except for Impact of Participation (after 1
year and at end of study)
Individual Level
Data: Affected
Child
• Clinical Symptoms • Completed by parent • Baseline and once a month
• Pediatric Evaluation of
Disability Inventory (PEDI©)
[45 47]
• Completed by RA through observation or parent
report
• Baseline and annually
Individual Level
Data: Sibling
• Kidcope[70] • Younger version completed by siblings age 7 to 12
years; older version for 13 to 18 years
All at baseline and every 6 months
• Child Behavior Checklist
(CBCL)[71]
• Completed by parent for siblings age 7 to18 years
• Youth Self Report (YSR)[72] • Completed by siblings age 11 to18 years and able to
complete by self
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system while the parent reports on the child’s symp-
toms. Parents were given the choice of administration
method for the symptoms’ instrument to allow flexibility
and accommodate any families lacking Internet access.
With assistance from the RA, the parent assesses the
ill child for cognitive and motor ability on enrolment
into the study and annually using the Pediatric Evalua-
tion of Disability Inventory (PEDI) [45-47]. In addition
to measuring functional abilities, the PEDI evaluates the
amount of Caregiver Assistance and Modifications
required in caring for the child. Data are collected using
this instrument from the time the family enrolls in the
study until the time of the child’s death or the end of
the data collection period, whichever comes first. RAs
complete the Caregiver Assistance and Modifications
section with the designated parent. To minimize poten-
tial error, all RAs involved with this study were trained
to complete the PEDI by an occupational therapist.
Further, to assess whether there is consistency across
the RAs’ ratings, inter-rater reliability testing was com-
pleted. Analysis of the reliability involved calculating the
Intra-class Correlation Coefficients (ICC) for the RA
scores on a sample case from the manual. Excellent cor-
relation among the RAs was found for Caregiver Assis-
tance, with an ICC value of 0.959 overall (Self-Care:
0.865; Mobility: 0.976; Social Function: 0.760). Testing
on the Modifications scale showed an ICC value of
0.651 overall (Self-Care: 0.550; Mobility: 0.674; Social
Function: 0.400). Reliability was high for the Caregiver
Assistance scale, and moderate-to-low for the Modifica-
tion scale. RAs received feedback about ways to improve
their administration of the tool in order to maintain
ongoing reliability.
Health records are reviewed by the RA at baseline to
document the circumstances surrounding the diagnosis
and the period leading up to the diagnosis, as well as
the prevalence and incidence of symptoms recorded
since diagnosis. If the child dies during the course of
the study, a chart review is conducted to document
details of the care provided just prior to the death and
the circumstances of the death. Chart reviews also will
be conducted for living children living at the conclusion
of the study.
Bio-psychosocial-spiritual stream
Data about the bio-psychosocial-spiritual experiences of
family members are collected at 6 month intervals, from
the time the family enrolls in the study until 6 months
prior to the end of the study (to allow for final analyses
and write-up), even if the child dies beforehand. The
outcomes being measured in the study include: family
functioning; marital satisfaction; parent health, anxiety,
depression, stress, burden, spirituality, grief, and growth;
and sibling health and coping. Most of the measures
have demonstrated reliability and validity and have been
widely used in previous research with similar popula-
tions. The exception is the instrument used to measure
grief, which was designed by the research team in con-
sultation with other experienced Canadian researchers.
The instrument is a modification of the Inventory of
Social Support (ISS), a 5-item self-report questionnaire
about what helps or makes it harder to cope with grief
[48]. The questionnaire package can be completed in
about one hour, as estimated by parents who pilot-
tested the instruments.
Unlike the clinical symptom stream where data are
collected online or by telephone, the bio-psychosocial-
spiritual instruments are completed at home and mailed
to the main site. This method of data collection allows
family members to complete questionnaires in their own
home, at their own pace, rather than having to commit
to a potentially lengthy interview time. At baseline, the
RA obtains permission to meet with the family during a
routine clinic visit or at another more convenient loca-
tion such as the family home, whichever is more amen-
able to the family. Once the baseline visit is complete,
no further face-to-face meetings with the family are
required. If the timing is appropriate and participants
want to complete subsequent questionnaires face-to-face
with the RA, then they may do so at the clinic visit.
Some of the children will likely die during the course
of the study; indeed, we already have faced this outcome
with one family. Clinicians involved with the child and
family notify the site RA when a child dies. The RA
immediately mails a hand-written card of condolence to
the family. The RA also conducts a chart review to
document the circumstances of the death. Other data
collection is suspended for the family until 6 months
after the child’s death. After that time, the RA contacts
the family by telephone to express condolences to the
family and obtain verbal agreement for continued parti-
cipation in the study. Data collection in the bio-psycho-
social-spiritual stream then continues at 6 month
intervals until the end of the study. Demographics are
updated at 6 month intervals throughout the study and
into the bereavement period.
Analysis Plan
Regardless of data collection method (in-person, on-line,
telephone, or mail) all data from the multiple sites are
entered into Daciforms, a single web-based database
(Dacima Software, Inc., Montreal, QC). Daciforms
allows researchers at multiple locations to enter and
review data online. Each study staff member is assigned
a unique password and Site ID that allows secure access
to the centralized data. From Daciforms, data are
exported into SPSS (IBM, Chicago) for descriptive analy-
sis. Once we have sufficient data points, advanced data
analysis and modeling will be performed using the
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open-source R statistical package (GNU General Public
License). Analysis for the clinical symptoms stream
involves describing the frequency and severity of symp-
toms based on the clinical symptom instrument. Follow-
ing the examination of simple descriptive tables, we will
fit longitudinal ordinal regression models including vari-
ables representing condition type (neurological, meta-
bolic, or chromosomal), time from diagnosis, age, and
sex. We will apply both hierarchical random effect [49]
and GEE (generalized estimating equation) [50] models.
Akaike’s Information Criterion (AIC) [51] will be used
to select terms (including interactions) in random-effect
models; resulting models will be re-fit using GEE to pro-
vide population-level estimates.
The symptom instrument includes items on change
relative to previous questionnaire administration based
on the expectation that ceiling effects will be modulated
by symptom progression. To capture this phenomenon,
we are defining a “symptom breakthrough” as occurring
if a symptom’s severity is at ceiling at time t but
reported to have worsened at time t+1. We will apply
longitudinal logistic regression models following the
general strategy outlined previously to describe patterns
of incidence.
Bio-psychosocial-spiritual measures will be analyzed in
a similar manner with descriptive statistics and longitu-
dinal regression models, and we will incorporate ran-
dom effects to allow for correlation within respondents
over time and between respondents within families.
Relationships between symptom progression and bio-
psychosocial-spiritual measures will be investigated in
an exploratory fashion. Due to the complex nature of
the data analysis, it was important to involve a statisti-
cian (RB) from the outset.
Ethical Issues
As part of designing the study, and in order to preemp-
tively address potential ethical concerns, we consulted
with parents of children who received pediatric palliative
care at Canuck Place Children’s Hospice in Vancouver.
These parents provided advice on timelines and fre-
quency of data collection. Parents highlighted two
issues: (1) the crucial need for this type of research and
(2) the potential need for emotional support to families.
RAs are sensitive to this potential need and have been
trained in how to communicate with families and to
ascertain whether support is needed. In addition, a
detailed list of institutional and community resources to
support families is available for each site and is given to
families on admission to the study. Families also are
reminded at each data collection point and in a semi-
annual newsletter that the list of resources is available.
The lists of local resources are updated semi-annually
and posted on the study website.
Limitations
One limitation that arose early on was the challenge of
defining a theoretical group of children with Quadrant 3
conditions using a rigorous “Inclusion/Exclusion
Criteria” checklist. Initially, clinicians were unsure what
Quadrant to categorize a diagnosis under and which chil-
dren could participate. However, the evolving Eligible
Disease List that was built from the ground up has
involved the clinicians in determining eligibility and has
encouraged their participation in refining the eventual
criteria. Rather than dictate the eligibility, the list has
been strengthened by ongoing discussion and iterative
review. While the current study focuses on families of
children with Quadrant 3-type life-threatening condi-
tions, it is anticipated that the method may be applied to
other groups of diseases. A similar process could be used
to identify eligibility in other studies. Researchers in
future studies could identify similarities and differences
amongst the Quadrants and build a comprehensive pic-
ture of important strategies within pediatric palliative
care to ensure optimal care for all affected families.
Another potential limitation inherent in the current
study design results from using multiple modalities of
data collection. We chose to use multiple modalities of
data collection (online, phone, written, and in-person)
throughout the study in order to provide the most flex-
ibility for participating families. There is some concern
in the literature that people respond differently to ques-
tions, particularly sensitive ones, based on the method
used to answer questions [52]. However, we believe that
it is most important for families to have some choice in
how they take part in the study and to choose what will
fit best with their schedule, lifestyle, and familiarity with
technology. This flexibility is important in minimizing
family burden related to the study and attrition of
families from the research. Our final data analysis will
reveal any differences in mode of data collection and its
possible impact on the research findings.
Lastly, instruments used in the study design are
entirely quantitative. The published instruments demon-
strate strong reliability and validity, therefore they were
the first choice for initial measurement of this uncharted
population. However we recognize the need for and
importance of also collecting qualitative data from
families. We have already had strong feedback from par-
ents about how important it is to “sit and talk” with the
families in order to better understand their full experi-
ence. Our hope is to obtain future funding, so that we
can expand on quantitative findings of our study
through interviews.
Discussion
Charting the Territory is a distinctive study because of
the focus on childhood conditions without cure or
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life-prolonging treatment; use of a prospective, longitu-
dinal design; and simultaneous attention to the affected
child, siblings, and parents. There is some reluctance to
conduct research with this population because of the
perceived negative impact on vulnerable families, how-
ever there is mounting evidence to suggest that partici-
pation in research during the illness experience and
after a child’s death is a positive experience for partici-
pants and should be conducted. Some studies have high-
lighted parents’ eagerness to share the story of their
child’s illness and death and to provide input to help
other families [53-55]. While parents report that discus-
sions of their child’s diagnosis and/or death are at times
difficult, the vast majority of parents deny any negative
impact or distress caused by participating in research
[56-60]. However, very few studies have included a sys-
tematic evaluation of the impact of participating in this
type of research, and none of the published studies eval-
uated a longitudinal study design.
To add to the small body of existing research and to
guide the study team in development of future longitu-
dinal studies with similar populations, we have incorpo-
rated a component to evaluate the impact on parents of
participating in the study. This evaluation will be com-
pleted by all participating parents through a written sur-
vey after one year of enrolment in the study and at the
end of the study. As well, at the end of the study the
RA will contact the designated parent by telephone to
debrief the experience and formally end the relationship
with the family. Any suggestions for how the process or
procedures of the study could be improved upon will be
sought formally at that time, but families also are
encouraged to provide feedback throughout the study. If
any other family members wish to speak directly with
the RA at the end of the study to provide feedback or
say goodbye, this conversation will be arranged. A final
personalized thank-you and good-bye letter will be sent
by the RA on behalf of the research team to the family
after this closure call.
We expect that this research will advance knowledge in
the fields of family caregiving, subspecialty pediatrics,
pediatric palliative care, and bereavement by providing
some of the first-ever detailed descriptions of the clinical
symptom trajectory and bio-psychosocial-spiritual aspects
for these conditions. We will close gaps in knowledge and
contribute to the limited, existing body of knowledge spe-
cific to Quadrant 3-type conditions in the emerging area
of pediatric palliative care. Extending existing research
will enable policy makers and practitioners to better
understand the realities of families where a child has a
progressive, life-threatening condition. Baseline informa-
tion about critical periods for symptom management and
psychosocial support will enable the design of appropriate
intervention and support strategies.
Specifically, the study will provide information to
families about what they might expect as the child’s ill-
ness progresses; assist with the development of symptom
assessment and evaluation tools, especially in non-verbal
children; provide critical information to pediatricians,
metabolic, genetics, and neurology specialists, family and
child health professionals, and pediatric palliative care
clinicians that will assist them to better support children
and families; provide a cohort and data to support inter-
ventional research in symptom management and care of
families; and lay the groundwork for future studies. As
noted by the parents, this study will help them learn
about expected trajectories; they will then use this
knowledge in decision-making and in advocating.
Currently, without this knowledge parents and health
professionals continue to ‘navigate uncharted territory.’
In this study the map needed to anticipate outcomes
and to guide informed decision-making throughout their
journey will be developed.
Acknowledgements
We wish to acknowledge funding from the Canadian Institutes of Health
Research (CIHR) for the New Emerging Team award (PET 69769), which
allowed us to develop the proposal for the current study. The current study
is funded as MOP 89984. Open access is a requirement of the funding
agency and was a consideration in the selection of BMC Pediatrics for
publication of this protocol. We also wish to thank the Site Lead
Collaborators who liaise with specialist clinicians to facilitate access to
research participants and guide the study through institutional ethics review,
as well as monitor study progress and provide timely updates at their
respective institutions; located in Calgary (Alberta Children’s Hospital Dr.
Sharron Spicer), Edmonton (Stollery Children’s Hospital Dr. Dawn Davies),
Toronto (The Hospital for Sick Children Dr. Adam Rapoport), Ottawa
(Children’s Hospital of Eastern Ontario Dr. Christina Vadeboncoeur), and
Montreal (Montreal Children’s Hospital Dr. Stephen Liben), in addition to
the research assistants at the participating sites: Lauren Campbell, Marilyn
Gordon, Jennifer MacInnis, Maryam Noghondarian, Rosa Alicia Paradelo, Silvia
Regina Zarow, Natalia Rincon, Megan Sloan and Edmund Tan.
Author details
1Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
2School of Nursing, York University, Toronto, ON, Canada. 3Child & Family
Research Institute, University of British Columbia, Vancouver, BC, Canada.
4Faculty of Social Work, Wilfrid Laurier University, Kitchener, ON, Canada.
5School of Nursing, University of Victoria, Victoria, BC, Canada. 6Faculty of
Nursing, University of Toronto, Toronto, ON, Canada.
Authors’ contributions
All authors made substantive intellectual contributions to conception and
design of this study and manuscript. HS and RS were the lead authors
responsible for initial drafting of the manuscript. All others, especially KW
and GA in the early revision stages, revised it critically for important
intellectual content. RB ensured the accuracy of the statistical information.
All authors read and approved the final manuscript.
Authors’ information
Dr. Harold Siden, MD, MHSc, FRCPC Clinical Associate Professor, Faculty of
Medicine, Department of Pediatrics, University of British Columbia
Developmental Neurosciences & Child Health, University of British Columbia
4480 Oak Street, Room F612A Vancouver, BC V6H 3V4 Canada Tel: (604) 875
2776 Fax: 604 875 2384 E mail: hsiden@cw.bc.ca
Dr. Rose Steele, RN, PhD Professor, School of Nursing Room 342 HNES
Building York University 4700 Keele Street Toronto, ON M3J 1P3 Canada Tel:
(416) 736 2100 ext. 40556 (work) Fax: (416) 736 5714 E mail: rsteele@yorku.ca
Siden et al. BMC Pediatrics 2010, 10:67
http://www.biomedcentral.com/1471 2431/10/67
Page 10 of 12
Dr. Rollin Brant, PhD Professor, Department of Statistics University of British
Columbia Child and Family Research Institute 4480 Oak Street, L408
Vancouver, BC, V6H 3V4 Canada Tel: 604 875 2000 x5389 Tel: 604 875 3570
(main office) Fax: 604 875 3569 E mail: rollin@stat.ubc.ca
Dr. Susan Cadell, PhD, MSW Associate Professor Director, Manulife Centre for
Healthy Living Lyle S. Hallman Faculty of Social Work Wilfrid Laurier
University 120 Duke St. West Kitchener, ON N2H 3W8 Canada Tel: (519) 884
0710 Ext. 5252 (office) Fax: (519) 888 9732 E mail: scadell@wlu.ca
Dr. Betty Davies, RN, PhD, FAAN Professor Emerita, School of Nursing
University of California San Francisco Professor and Senior Scholar, School of
Nursing University of Victoria PO Box 1700 STN CSC Victoria, BC V8W 2Y2
Canada Tel: (250) 721 6467 Fax: (250) 721 6231 E mail: betty.davies@nursing.
ucsf.edu
Dr. Lynn Straatman, MD, FRCPC Clinical Assistant Professor, Faculty of
Medicine, Department of Cardiology, University of British Columbia c/o
Canuck Place Children’s Hospice 1690 Matthews Ave. Vancouver, BC V6J 2T2
Canada Tel: (604) 806 9356 (office) Fax: (604) 806 8763 E mail: Lynn.
Straatman@vch.ca
Kimberley Widger RN PhD(c) CHPCN(C) Lawrence S. Bloomberg Faculty of
Nursing University of Toronto 155 College Street, Suite 130 Toronto, ON,
M5T 1P8 Canada Tel: 416 946 3928 Fax: 416 978 8222 E mail: kim.
widger@utoronto.ca
Gail S Andrews, MEd Developmental Neurosciences & Child Health University
of British Columbia 4480 Oak St., Room F615 Vancouver, BC V6H 3V4 Canada
Tel: (604) 875 2000 Ext. 5345 Fax: 604 875 2384 E mail: gandrews@cw.bc.ca
Competing interests
The authors declare that they have no competing interests.
Received: 24 June 2010 Accepted: 20 September 2010
Published: 20 September 2010
References
1. Statistics Canada: Mortality, summary list of causes. Ottawa 2003 [http://
www.statcan.gc.ca/pub/84f0209x/84f0209x2003000 eng.pdf].
2. Public Health Agency of Canada: Economic burden of illness in Canada,
1998. Ottawa 1998 [http://www.phac aspc.gc.ca/publicat/ebic femc98/pdf/
ebic1998.pdf].
3. American Academy of Pediatrics. Committee on Bioethics and Committee
on Hospital Care: Palliative care for children. Pediatrics 2000, 106:351 357.
4. Cooley C, Adeodu S, Aldred H, Beesley S, Leung A, Thacker L: Paediatric
palliative care: a lack of research based evidence. Int J Palliat Nurs 2000,
6:346 351.
5. Hunt A, Hain R, Jassal S, Thompson A: Pediatric palliative care: where and
what is published? Arch Dis Child 2003, 88(Suppl 1):A61 A63.
6. Hutton N: Pediatric palliative care: the time has come. Arch Pediatr
Adolesc Med 2002, 156:9 10.
7. Field MJ, Behrman RE, Eds: When children die: improving palliative and
end of life care for children and their families. Washington, D.C.: The
National Academies Press 2003.
8. Steele R, Bosma H, Fletcher Johnston M, Cadell S, Davies B, Siden H,
Straatman L: Research priorities in pediatric palliative care: a Delphi
study. J Palliat Care 2008, 24:229 230, 287.
9. Steele R, Davies B: Impact on parents when a child has a progressive,
life threatening illness. Int J Palliat Nurs 2006, 12:576 585.
10. Steele R: Navigating uncharted territory: experiences of families when a
child is dying. J Palliat Care 2005, 21:35 43.
11. Steele R: Strategies used by families to navigate uncharted territory
when a child is dying. J Palliat Care 2005, 21:103 110.
12. Steele RG: Experiences of families in which a child has a prolonged
terminal illness: modifying factors. Int J Palliat Nurs 2002, 8:418 434.
13. Steele RG: Trajectory of certain death at an unknown time: children with
neurodegenerative life threatening illnesses. Can J Nurs Res 2000,
32:49 67.
14. Association for Children with Life Threatening or Terminal Conditions and
their Families (ACT), Royal College of Paediatrics and Child Health: A guide
to the development of children’s palliative care services. London: Royal
College of Paediatrics and Child Health, 2 2003.
15. Schneider M, Steele R, Cadell S, Hemsworth D: Differences on psychosocial
outcomes between male and female caregivers of children with life
limiting illnesses. J Pediatr Nurs 2010.
16. Stein A, Woolley H: An evaluation of hospice care for children. In Listen:
My Child Has a Lot of Living to Do. Edited by: Baum J, Dominica F,
Woodward R. Oxford, UK: Oxford University Press; 1990:66 90.
17. Davies B, Howell D: Special services for children. In Oxford Textbook of
Palliative Medicine. Edited by: Doyle D, Hanks G, MacDonald N. Oxford, UK:
Oxford University Press; , 2 1998:1077 1084.
18. Goldman A: Home care of the dying child. J Palliat Care 1996, 12:16 19.
19. Hunt A, Burne R: Medical and nursing problems of children with
neurodegenerative disease. Palliat Med 1995, 9:19 26.
20. Hunt AM: A survey of signs, symptoms and symptom control in 30
terminally ill children. Dev Med Child Neurol 1990, 32:341 6.
21. McQuillan R, Finlay I: Facilitating the care of terminally ill children. J Pain
Symptom Manage 1996, 12:320 4.
22. Woolley H, Stein A, Forrest GC, Baum JD: Cornerstone care for families of
children with life threatening illness. Dev Med Child Neurol 1991,
33:216 224.
23. Feudtner C, Hays RM, Haynes G, Geyer JR, Neff JM, Koepsell TD: Deaths
attributed to pediatric complex chronic conditions: national trends and
implications for supportive care services. Pediatrics 2001, 107:E99.
24. Feudtner C, Christakis DA, Connell FA: Pediatric deaths attributable to
complex chronic conditions: a population based study of Washington
State, 1980 1997. Pediatrics 2000, 106:205 209.
25. Goldman A, Hewitt M, Collins GS, Childs M, Hain R, United Kingdom
Children’s Cancer Study Group/Paediatric Oncology Nurses’ Forum Palliative
Care Working Group: Symptoms in children/young people with
progressive malignant disease: United Kingdom Children’s Cancer Study
Group/Paediatric Oncology Nurses Forum survey. Pediatrics 2006, 117:
e1179 86.
26. Parker M: Families caring for chronically ill children with tuberous
sclerosis complex. Fam Community Health 1996, 19:73 85.
27. Davies H: Living with dying: families coping with a child who has a
neurodegenerative genetic disorder. Axon 1996, 18:38 44.
28. Konrad SC: Posttraumatic growth in mothers of children with acquired
disabilities. J Loss Trauma 2006, 11:101 101 113.
29. Stainton T, Besser H: The positive impact of children with an intellectual
disability on the family. J Intellect Dev Disabil 1998, 23:57 70.
30. Barlow JH, Ellard DR: The psychosocial well being of children with
chronic disease, their parents and siblings: an overview of the research
evidence base. Child Care Health Dev 2006, 32:19 31.
31. Davies B: Shadows in the sun: the experiences of sibling bereavement in
childhood Philadelphia: Brunner/Mazel 1999.
32. Davies B: After a child dies: helping the siblings. In Hospice Care for
Children. Edited by: Goltzer S, Armstrong Dailey A. New York, NY: Oxford
University Press; , 2 2001:157 171.
33. Feudtner C, Feinstein JA, Satchell M, Zhao H, Kang TI: Shifting place of
death among children with complex chronic conditions in the United
States, 1989 2003. JAMA 2007, 297:2725 2732.
34. Bruera E: Ethical issues in palliative care research. J Palliat Care 1994,
10:7 9.
35. Given BA, Keilman LJ, Collins C, Given CW: Strategies to minimize attrition
in longitudinal studies. Nurs Res 1990, 39:184 186.
36. Sherman DW, McSherry CB, Parkas V, Ye XY, Calabrese M, Gatto M:
Recruitment and retention in a longitudinal palliative care study. Appl
Nurs Res 2005, 18:167 177.
37. Steinhauser KE, Clipp EC, Hays JC, Olsen M, Arnold R, Christakis NA,
Lindquist JH, Tulsky JA: Identifying, recruiting, and retaining seriously ill
patients and their caregivers in longitudinal research. Palliat Med 2006,
20:745 754.
38. Janus M, Goldberg S: Factors influencing family participation in a
longitudinal study: comparison of pediatric and healthy samples. J
Pediatr Psychol 1997, 22:245 262.
39. Folkman S, Chesney MA, Christopher Richards A: Stress and coping in
caregiving partners of men with AIDS. Psychiatr Clin North Am 1994,
17:35 53.
40. Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem Schatz S,
Emanuel EJ, Weeks JC: Symptoms and suffering at the end of life in
children with cancer. N Engl J Med 2000, 342:326 333.
41. Dussel V, Aldridge SE, Kang T, Feudtner C, Cook EF, Weeks JC, Wolfe J:
Feasibility of conducting a Randomized Controlled Trial (RCT) in children
with advanced cancer: lessons from the Pediatric Quality of Life and
Evaluation of Symptoms Technology (PediQuest) Study [poster]. The
Siden et al. BMC Pediatrics 2010, 10:67
http://www.biomedcentral.com/1471 2431/10/67
Page 11 of 12

